Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 17/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624076 | 1.00 | MAPT (0.54) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3620938 | 0.82 | MAPT (0.72) | MAPTKMT2AALDH1A1MAPK1 | |
| SCHEMBL22095026 | 0.80 | MAPT (0.55) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3616157 | 0.79 | MAPK1 (0.74) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3616153 | 0.79 | MAPK1 (0.74) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3620206 | 0.78 | KEAP1 (0.48) | MAPTKMT2AALDH1A1MEN1HTT | |
| SCHEMBL3621735 | 0.78 | MAPT (0.43) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3621737 | 0.78 | MAPT (0.43) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3621035 | 0.77 | BCL2 (0.52) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL22095447 | 0.77 | THRB (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | MAPT 2577/4885KMT2A 2498/4885ALDH1A1 438/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | MAPT 2577/4885KMT2A 2498/4885ALDH1A1 438/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | MAPT 2697/4885KMT2A 2290/4885ALDH1A1 818/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | MAPT 2697/4885KMT2A 2290/4885ALDH1A1 818/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | MAPT 2697/4885KMT2A 2290/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.